Phenylbutazone Powder






For oral use in horses only

Phenylbutazone is a synthetic, non-hormonal, anti-inflammatory agent that is indicated for the relief of inflammatory conditions associated with the musculoskeletal system in horses. This highly palatable citrus-flavored powder is sweetened with natural sugar and is easily top-dressed on the horse's ration, and is dosed at 0.6–1.2 oz. per 500 lbs. of body weight. Each 10 grams of powder contains 1 gram of phenylbutazone. Prescription.

ITEM#	DESCRIPTION	SIZE
511037	Phenylbutazone Powder	1.1 lb
510037	Phenylbutazone Powder	2.2 lb





Phenylbutazone Powder







Powder

For Oral Use In Horses Only NON-STEROIDAL ANTI-**INFLAMMATORY DRUG (NSAID)**

ANADA 200-334, Approved by FDA

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this product in female dairy cattle 20 months of age

DESCRIPTION: Phenylbutazone chemically is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione. C₁₉H₂₀N₂O₂

Mol. Wt. 308.38

Each 10 grams of powder contains 1 gram phenylbutazone

INDICATIONS: Phenylbutazone is for the relief of inflammatory conditions associated with the musculoskeletal system in horses. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy should be used concurrently.

DOSAGE AND ADMINISTRATION:

For Horses Only: Administer orally (using the 0.6 ounce (18 mL) scoop provided) on a small amount of palatable feed and mix well.

Give 1 to 2 level scoops per 500 pounds of body weight, but do not exceed 4 scoops per animal daily. Use the high dose for the first 48 hours, then gradually reduce to a maintenance dose.

CONTRAINDICATIONS: Use with caution in patients who have history of drug allergy.

WARNING: Do not use in horses intended for human consumption.

HUMAN WARNINGS: Keep this and all medications out of the reach of children. Dispense in tight, child resistant containers. **PRECAUTION:** Concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored.

CLINICAL PHARMACOLOGY: Phenylbutazone was first synthesized in 1948 and introduced into human medicine in 1949. Kuzell (1), (2), (3), Payne (4), Fleming (5) and Denko (6) demonstrated the clinical effectiveness of phenylbutazone in gout, gouty arthritis, acute arthritis, acute rheumatism and various other rheumatoid disorders in humans. Fabre (7), Domenioz (8), Wilhelmi (9) and Yourish (10) have established the anti-rheumatic and antiinflammatory activity of phenylbutazone. It is entirely unrelated to the steroid hormones.

Toxicity of phenylbutazone has been investigated in rats and mice (11) and dogs (12).

Phenylbutazone has been used by Camberos (13) in thoroughbred horses. Favorable results were reported in cases of traumatism, muscle rupture, strains and inflammations of the third phalanx. Results were not as favorable in the period treatment of osteoarthritis of the stifle and hip, arthrosis of the trapezius muscles and general arthritis. Sutter (14) reported a favorable response in chronic equine arthritis of long duration, fair results in severely bruised mare and poor results in two cases where the condition was limited to the third phalanx.

HOW SUPPLIED: Phenylbutazone Powder is supplied in 2.2 lb (1 kg) jars each containing a dispensing scoop.

One level scoop delivers 10 grams of powder containing 1 gram of phenylbutazone.

Store at room temperature, 15°-30°C (59°-86°F).

References:

- 1. Kuzell, WC, Schaffarzick, RW, Naughler, WE, Gandia, C, and Mankle, EA: A.M.A. Arch. Inst. Med., 92:646 (1953).
- 2. Kuzell, WC, Schaffarzick, RW, Brown, B, and Mankle, EA: J.A.M.A., 149:729 (1952).
- 3. Kuzell, WC, and Schaffazick, RW: Calif. Med., 77:319 (1952).
- 4. Payne, RW, Shelter, MR, Farr, CH, Hellbaum, AA, and Ishmall, WK: J. Lab. Clin. Med., 45:331 (1955).
- 5. Fleming, J, and Will, G: Ann. Rheumat., Dis., 12:95 (1953).
- 6. Denko, CW, and Rumi, D: American Pract., 6:1865 (1955).
- 7. Fabre, J, et al: Semain. Hop. (Paris), 31:87 (1955). Domenjoz, R, et al: Arzneimittel-Forsch, 5:488 (1955).
- 8. Wilhelmi G, and Pulver, R: Arzneimittel-Forsch, 5:221 (1955).
- 9. Yourish, W, Paton, B, Brodie, B, and Burns, J: A.M.A. Arch. Ophth., 53:264 (1955).
- 10. Hazelton, LW, Tusing, TW, and Hollana, EG: J. Pharmacol. Exper. Ther., 109:387 (1953).
- 11. Ogilvie, FB, and Sutter, MD: Vet. Med. 52:492 (1957).
- 12. Camberos, HR: Rev. Med. Vet. (Buenos Aires), 38:9 (1956).
- 13. Sutter, MD: Vet. Med., 53:83 (1958).